Table 2. Effect of Treatment with CMX001 or ACV on Mortality of BALB/c Mice Inoculated Intranasally with HSV-2 strain MS.

	Mortality
Treatmenta	Number	Percent	p-Value	MDD±SDb	p-Value
+ 24 h
Untreated	14/15	93	---	9.4 ± 2.3	---
Vehicle	15/15	100	---	7.9 ± 1.1	---
ACV 120 mg/kg	0/15	0	<0.001	---	---
60 mg/kg	1/15	7	<0.001	9.0	NSc
30 mg/kg	3/15	20	<0.001	11.3 ± 1.2	<0.01
CMX001 5 mg/kg	0/15	0	<0.001	---	---
2.5 mg/kg	2/15	13	<0.001	10.5 ± 0.7	<0.05
1.25 mg/kg	7/15	47	<0.001	9.4 ± 1.4	<0.05
+ 48 h
Vehicle	12/15	80	---	9.8 ± 2.7	---
ACV 120 mg/kg	0/15	0	<0.001	---	---
60 mg/kg	1/15	7	<0.001	14.0	NS
30 mg/kg	1/15	7	<0.001	9.0	NS
CMX001 5 mg/kg	1/15	7	<0.001	11.0	NS
2.5 mg/kg	4/15	27	<0.001	10.5 ± 2.5	NS
1.25 mg/kg	3/15	20	<0.001	10.3 ± 2.1	NS
+ 72 h
Vehicle	13/15	87	---	8.9 ± 1.1	---
ACV 120 mg/kg	9/15	60	<0.05	9.0 ± 1.4	NS
60 mg/kg	4/15	27	<0.001	11.5 ± 2.6	0.07
30 mg/kg	5/15	33	<0.001	11.0 ± 3.1	NS
CMX001 5 mg/kg	11/15	73	NS	9.4 ± 1.6	NS
2.5 mg/kg	6/15	40	0.001	11.8 ± 3.7	<0.05
1.25 mg/kg	4/15	27	<0.001	10.0 ± 1.8	NS

^aCMX001 was suspended in 0.4% CMC and given orally in 0.2 ml doses. ACV was prepared in sterile water and given orally in 0.2 ml doses. Animals were treated with CMX001 once daily or with ACV twice daily for seven days beginning 24, 48, or 72 h after viral inoculation.

^bMDD = Mean Day of Death. SD=Standard Deviation.

^cNS = Not significant when compared to the vehicle control group.